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S168 Oral Presentations3 adeno patients had detectable hexon-specific response (11 SFC/
110e5 cells), however, none of the 5 CMV+ patients had any
detectable SFC. However, after 9-12 days of stimulation we could
enumerate CTLp in 7/8 patients. For adenovirus, the median
hexon-specific response was 52 SFC/110e5 SFC (range 20-90),
and the penton-specific CTLp frequency was 13 SFC/110e5
(1 – 25). The median CMV pp65-specific response was 6.7 SFC/
110e5 (0-14).No responses were recorded against CMVEI-1 dem-
onstrating the critical role of antigenic restimulation by the
Ad5f35pp65 construct lacking IE. Smilarly in the adeno+/CMV-
patients we detected SFC solely against hexon and/or penton. All
patients are surviving at a median of 220 days after transplant (range
81-532).
Conclusion: To our knowledge these are the first data demonstrat-
ing that dormant virus-specific CTLp are present already in the first
2-3 months in most adenovirus or CMV infected UCBT recipients
(7/8 in this dataset). Although these rare events are below detection
by standard ELISPOT the feasibility of their ex vivo expansion may
lead to adoptive therapies.GVH/GVL
36
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In lung transplantation, early infection (\100 d) with a common
respiratory virus (RV) is associated with acute or chronic rejection,
presenting as Bronchiolitis Obliterans (BO). After hematopoietic
stem cell transplantation (HSCT) alloimmune lung syndromes
(allo-LS), including Idiopathic Pneumonia Syndrome (IPS; acute)
and BO (chronic), also occur, but the role of RV is unclear. In
this prospective cohort study we analyzed the influence of common
RV early (\ 100 days) after HSCT, on the development of allo-LS
and survival. 110 paediatric patients with a median age of 5 years (2
mths – 21years), were included. They received a transplant (56
matched, 54 mismatched; 33 cord blood, 77 bone marrow; 33 fam-
ily, 77 unrelated) for malignant (56) and non-malignant (54) dis-
ease, after a TBI (33) or chemotherapy based (77) conditioning
regimen. In 50% of patients a RV infection occurred, at a median
of day +16 (range -7 to 100). RV was proven by qPCR on nasopha-
ryngeal aspirate: Rhinovirus was found most frequent (28), fol-
lowed by Parainfluenzavirus1-3, Coronavirus, Influenza A virus
and Adenovirus. Clinical symptoms were mild, and all patients re-
covered spontaneously, despite the fact that the RV remained pres-
ent for months in all patients. After a period without symptoms of
at least 2 weeks, new respiratory symptoms occurred in about 50%
of the RV positive patients. Based on additional examinations
including negative cultures (other than RV), radiology and pulmo-
nary function tests, 30 patients (27.2%) were diagnosed with allo-
LS: 18 IPS (16.4%) and 12 BO (10.9%), after a median time of 8
weeks (2-26). Multivariable analysis showed that RV infection is
an important predictor for allo-LS (p\0.0001). There was no
difference between Rhinovirus versus all others. Acute Graft-
versus-Host Disease (aGVHD), occurring at a median of 4 weeks
(2-15), had a protective effect on the development of allo-LS
(p5 0.004), most likely due to higher and prolonged immunesup-
pression in these patients. Overall survival was 73%; in the allo-LS
group this was only 53%. In multivariable analysis allo-LS was the
only predictor for mortality (p5 0.04).
In conclusion, early presence of RV is a predictor for the develop-
ment of allo-LS.We hypothesise that infection with a common cold
virus makes the lung a target for alloimmunity, leading to life threat-
ening lung disease. Paradoxically, prolonged immune suppression,
despite the local viral infection, protected against the development
of allo-LS.37
RAPID RECONSTITUTION OF THE REGULATORY T CELL COMPARTMENT
AFTER HIGH DOSE CYCLOPHOSPHAMIDE IMMUNOSUPPRESSION PRE-
VENTS THE DEVELOPMENT OF GVHD AFTER ALLOGENEIC BMT
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Graft-versus-host disease (GVHD) is a life-threatening complica-
tion of allogeneic bone marrow transplantation (BMT). Although
the development of immunosuppressive regimens has reduced the
incidence and severity of this post transplant complication, GVHD
continues to be a significant clinical problem. There is also signifi-
cant toxicity associated with the multi-agent immunosuppressive
regimens. Recent studies revealed that high dose cyclophosphamide
(Cy, 50 mg/kg) was effective at reducing the incidence of grades
II-IV GVHD when administered as a single agent on days 3 and 4
following HLAmatched related and unrelated BMT. The incidence
of chronic GVHD was also reduced to 10%. The present studies
evaluated the reconstitution of the CD4 +CD25 + Foxp3+ regula-
tory T cell compartment in patients treated with single agent high
dose Cy. Peripheral blood lymphocytes (50 patients) were harvested
on days 30, 45 and 60 post transplant and evaluated for Foxp3, IL-2
and IFN-g mRNA transcript levels by real time PCR and by enu-
meration of CD4 +CD25 + Foxp3 + T cells by flow cytometry.
The results reveal that there was an inverse correlation of Foxp3
mRNA transcripts with the incidence of grades II-IVGVHD.Levels
of Foxp3 mRNA transcripts in patients who did not develop GVHD
were .100 fold greater than the levels detected in patients who de-
veloped GVHD. Interestingly, mRNA transcript levels of IL-2 and
IFN-g were significantly increased (.100-1000 fold) in patients
developing acute GVHD. Additional studies revealed that CD4 +
CD25 + Foxp3 + T cells enumerated flow cytometrically in a subset
of patients (16) were also detected at significant levels (30-50 cells/
ul) as early as day 30 in patients who did not develop GVHD. Com-
paratively, the number of CD4 +CD25 + Foxp3 + T cells in patients
who developed acute GVHD was\10 cells/ul and remained persis-
tently low even at day 60. The peripheral blood mononuclear cells
were also assessed for T cell recombinant excision circles (TRECs)
as a marker for recent thymic emigrants. Surprisingly, TRECs
were not detected at day 30. Taken together, these results suggest
that there is a rapid recovery of CD4 +CD25 + Foxp3+ regulatory
T cells in the majority of patients treated with high dose Cy which
may prevent the development of GVHD. The absence of TRECs
in these patients may suggest that the expansion of the regulatory
compartment may be antigen driven from amature T cell population
or expanded by homeostatic mechanisms.38
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Introduction:Despite the inadequacy of currentGvHDprophylaxis
for MHC-mismatched HSCT, the introduction of novel therapeu-
tics has been slow, likely due to the lack of a suitable translational
model to rigorously test emerging therapies.Herewedescribe anovel
Rhesusmacaquemodel,whichhas allowedus to evaluatemechanisms
controlling GvHD and its protection in a primate translational sys-
tem.
Methods: Using microsatellite-based MHC haplotyping, we devel-
oped the first MHC-defined primate HSCT system. HSCT recipi-
ents, prepared with 8 Gy TBI, received either no
immunosuppression or a costimulation blockade-based regimen
which included CD28 blockade (abatacept), CD40 blockade (with
the anti-CD40 antibody 3A8) and sirolimus after MHC haploident-
ical sibling HSCT. Recipients received a TNC dose of 9.3 +/-
2.7108/kg and a CD3+ cell dose of 1.1 +/- 0.88  108/kg.
Results: Three control recipients (no immunosuppression) demon-
strated rapid and complete donor engraftment, with T cell activation
and proliferation occurring by Day 7, coincident with the onset of
severe clinical GvHD. Flow cytometric analysis showed loss of
